EQS-Adhoc

Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab

EQS-Ad-hoc: MorphoSys AG / Key word(s): Mergers & Acquisitions/Disposal Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab 05-Feb-2024 / 22:45 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014

 

Planegg/Munich, Germany, February 5, 2024

 

 

Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab

MorphoSys AG (FSE: MOR; NASDAQ: MOR) announces today that it entered into a Business Combination Agreement with Novartis data42 AG and Novartis AG (hereinafter collectively referred to as "Novartis") based on Novartis' intention to submit a voluntary public takeover offer (the "Takeover Offer") for all of MorphoSys' outstanding common shares in exchange for payment of € 68.00 per share. As part of the Business Combination Agreement with Novartis, Novartis seeks to obtain exclusive, worldwide rights to develop and commercialize pelabresib, an investigational BET inhibitor, and tulmimetostat, an investigational next-generation dual inhibitor of EZH2 and EZH1, across all indications. Separately, MorphoSys entered into a Purchase Agreement with Incyte Corporation to sell and transfer all rights worldwide related to tafasitamab for $ 25.0 million. Currently, MorphoSys partners with Incyte on the development and commercialization of tafasitamab. MorphoSys' Management Board and Supervisory Board unanimously approved both agreements.